Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUMAS: HisproUK and low-dose alteplase for ischemic stroke
NCT04256473Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Aug 2019
- Primary completion
- Mar 2022
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of mutant pro-urokinase in ischemic stroke, sponsored by Erasmus MC. Started Aug 2019; status: completed.
02
Drugs
mutant pro-urokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04256473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256473.